These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 29283396)

  • 1. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
    Daly AK; Rettie AE; Fowler DM; Miners JO
    J Pers Med; 2017 Dec; 8(1):. PubMed ID: 29283396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
    Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
    Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
    Sagreiya H; Berube C; Wen A; Ramakrishnan R; Mir A; Hamilton A; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):407-13. PubMed ID: 20442691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
    Ndadza A; Muyambo S; Mntla P; Wonkam A; Chimusa E; Kengne AP; Ntsekhe M; Dandara C
    J Thromb Haemost; 2021 Dec; 19(12):2957-2973. PubMed ID: 34382722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
    Lindley KJ; Limdi NA; Cavallari LH; Perera MA; Lenzini P; Johnson JA; Wu AHB; Ridker PM; King CR; Eby CS; Patel S; Shah SV; Beasley TM; Li J; Gage BF
    Clin Pharmacol Ther; 2022 Apr; 111(4):950-955. PubMed ID: 35108398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
    Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
    Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Assessment of 12 Rare Allelic
    Kumondai M; Ito A; Gutiérrez Rico EM; Hishinuma E; Ueda A; Saito S; Nakayoshi T; Oda A; Tadaka S; Kinoshita K; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33540768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 polymorphisms are associated with reduced warfarin dose.
    Freeman BD; Zehnbauer BA; McGrath S; Borecki I; Buchman TG
    Surgery; 2000 Aug; 128(2):281-5. PubMed ID: 10923005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.
    Scheer N; Kapelyukh Y; Chatham L; Rode A; Buechel S; Wolf CR
    Mol Pharmacol; 2012 Dec; 82(6):1022-9. PubMed ID: 22918969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
    Hillman MA; Wilke RA; Yale SH; Vidaillet HJ; Caldwell MD; Glurich I; Berg RL; Schmelzer J; Burmester JK
    Clin Med Res; 2005 Aug; 3(3):137-45. PubMed ID: 16160068
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.